Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 52-week Safety Study of QVM149 in Japanese Patients With Asthma
jRCT2080223529Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma, sponsored by Novartis. Started May 2017; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2080223529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223529.